FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIA	AL OWNERSHIP

OMB APPRO	VAL						
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						
	OMB Number: Estimated average burde						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Walker Neal</u>					2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS]						_	ner				
(Last) (First) (Middle) C/O ACLARIS THERAPEUTICS, INC. 101 LINDENWOOD DRIVE, SUITE 400					3. Date of Earliest Transaction (Month/Day/Year) 12/18/2015					>	X Officer (give title Other (specify below) President and CEO					
(Street) MALVE (City)		A tate)	19355 (Zip)	4	4. If Amendment, Date of Original Filed (Month/Day/Year)				6. Inc Line)							
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			te	action ZA. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.				5. Amoun Securities Beneficia Owned Fo	s lly ollowing (6. Owne Form: E (D) or Ir (I) (Insti	Direct II ndirect E r. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code V	Amount	(A) oi (D)	Price	Transacti (Instr. 3 a	ion(s)			(1115(1.4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	rative Conversion Date Execution Date, Trity or Exercise (Month/Day/Year) if any C		Code	nsaction Derivative E		Expiration Date of S (Month/Day/Year) Und Deri		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio	y C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	11(5)		
Stock option (right to buy)	\$28.68	12/18/2015		A		137,335		(1)	12/17/2025	Common Stock	137,335	\$0.00	137,335	5	D	
Restricted stock units	(2)	12/18/2015		A		11,700		(3)	(3)	Common Stock	11,700	\$0.00	11,700		D	

Explanation of Responses:

- 1. The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant.
- 2. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- 3. The shares underlying these restricted stock units vest in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Remarks:

/s/ Brian F. Leaf, Attorney-infact 12/22/2015

** Signature of Reporting Person Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.